Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;188(1):77-89.
doi: 10.1007/s10549-021-06173-z. Epub 2021 Mar 16.

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

Young-Hyuck Im  1 , Bulent Karabulut  2 , Keun Seok Lee  3 , Byeong-Woo Park  4 , Aditya Adhav  5 , Havva Yesil Cinkir  6 , Hikmat Abdel-Razeq  7 , Yuan-Ching Chang  8 , Sercan Aksoy  9 , Seock-Ah Im  10 , Joon Jeong  11 , Yeesoo Chae  12 , James Bowles  13 , Khemaies Slimane  13 , Hongling Xue  14 , Sung-Bae Kim  15
Affiliations

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

Young-Hyuck Im et al. Breast Cancer Res Treat. 2021 Jul.

Abstract

Background: This study was conducted to collect clinical safety, tolerability, and efficacy data with the use of everolimus (EVE) combined with exemestane (EXE) in patients with advanced breast cancer (ABC).

Methods: The EVEREXES trial initiated in 2012, provided early access to the first dual blockade treatment with EVE + EXE in patients with HR+, HER2 - ABC in Asia and other emerging growth countries. Postmenopausal women with HR+, HER2 - ABC who had documented recurrence or progression, following a nonsteroidal aromatase inhibitor therapy, were treated with EVE (10 mg/day) + EXE (25 mg/day) orally.

Results: A total of 235 patients received ≥ 1 dose of study medication. At the end of the study, all patients ceased the treatment. Disease progression (66.0%) was the primary reason of discontinuation. The most common AEs (≥ 20%) were stomatitis, decreased appetite, hyperglycemia, rash, aspartate aminotransferase increased, anemia, alanine aminotransferase increased, cough, and fatigue. No new safety concerns were identified in the current study. Median progression-free survival (PFS) in the Asian subset was similar to that of the overall population (9.3 months in both groups). Confirmed overall response rate (ORR) was achieved for 19.6% of the patients. Efficacy of EVE + EXE across subgroups (prior CT, line of treatment, and presence of visceral metastases) was maintained.

Conclusion: The safety and efficacy results from EVEREXES trial are consistent to data previously reported in BOLERO-2. These results support that EVE + EXE could be a viable treatment option for the postmenopausal women with HR+, HER2 - ABC in Asian region.

Keywords: Breast Cancer; EVEREXES; Everolimus; Exemestane; HER2 −; HR +; Mammalian target of rapamycin (mTOR).

PubMed Disclaimer

References

    1. Breast cancer, early diagnosis and screening (2020) https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ . Accessed 6 Nov 2020
    1. Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS (2019) Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression. Breast Cancer Res Treat 177:549–559. https://doi.org/10.1007/s10549-019-05318-5 - DOI - PubMed
    1. El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, Seoud M, Shamseddine AI (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5:225–233. https://doi.org/10.1016/j.ijsu.2006.06.015 - DOI - PubMed
    1. Youlden DR, Cramb SM, Yip CH, Baade PD (2014) Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 11:101–115. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005 - DOI - PubMed - PMC
    1. Sammons S, Kornblum NS, Blackwell KL (2019) Fulvestrant-based combination therapy for second-line treatment of hormone receptor-positive advanced breast cancer. Target Oncol 14:1–12. https://doi.org/10.1007/s11523-018-0587-9 - DOI - PubMed

LinkOut - more resources